TScan Therapeutics to reduce workforce by 30%

TScan Therapeutics (TCRX) announced regulatory and clinical program updates, implementation of a workforce reduction of approximately 30%, and extension of its cash runway into the second half of 2027. The strategic prioritization is expected to produce annual cost savings of $45.0M in 2026 and 2027, and will impact approximately 30% of the Company’s workforce, or 66 employees. The Company expects to record a one-time charge of up to approximately $2.3M in the Q4 for severance-related benefits and other costs. Following a productive End-of-Phase 1 meeting with the FDA, the Company has reached alignment on the registrational path forward for the TSC-101 program as a treatment for acute myeloid leukemia, or AML, and myelodysplastic syndromes, or MDS. The pivotal study will mirror TScan’s ongoing Phase 1 study, using a biologically assigned internal control arm to support relapse-free survival as the primary endpoint. Through a strategic prioritization, the Company will advance clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on developing in vivo-engineered TCR-Ts for solid tumors and on target discovery for autoimmunity. In connection with this strategy, the Company’s workforce is being reduced by approximately 30%, or 66 employees. Upcoming anticipated milestones include. Plans to present updated clinical data on Phase 1 ALLOHA trial at ASH on December 6 in Orlando, Florida; Plans to submit INDs for two additional TCR-T product candidates to expand HLA coverage of the heme program in Q4 2025; Plans to launch pivotal trial for TSC-101 for patients with AML and MDS in Q2 2026.